EXACT Therapeutics Valuation

Is EXTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EXTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EXTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EXTX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXTX?

Key metric: As EXTX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for EXTX. This is calculated by dividing EXTX's market cap by their current book value.
What is EXTX's PB Ratio?
PB Ratio	10.5x
Book	NOK 17.44m
Market Cap	NOK 182.86m

EXTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does EXTX's PB Ratio compare to its peers?

The above table shows the PB ratio for EXTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3.3x
LYTIX Lytix Biopharma	9.2x	n/a	NOK 337.4m
NANOV Nordic Nanovector	3.6x	n/a	NOK 231.8m
ABS Arctic Bioscience	0.2x	-12.8%	NOK 50.7m
ULTI Ultimovacs	0.4x	25.5%	NOK 74.3m
EXTX EXACT Therapeutics	10.5x	n/a	NOK 182.9m

Price-To-Book vs Peers: EXTX is expensive based on its Price-To-Book Ratio (10.5x) compared to the peer average (3.3x).

Price to Book Ratio vs Industry

How does EXTX's PB Ratio compare vs other companies in the European Biotechs Industry?

16 Companies	Price / Book	Estimated Growth	Market Cap

16 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: EXTX is expensive based on its Price-To-Book Ratio (10.5x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is EXTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	10.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate EXTX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.